AN2 director sells 16,119 shares around $6

Director-associated funds sold 16,119 ANTX shares under pre-set Rule 10b5-1 plans, while the director continues to hold shares directly.

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock associated with investment funds MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on September 3 and 8, 2026. The funds sold a total of 16,119 shares at weighted average prices of $6.0183 and $6.0698 per share, for transactions occurring automatically pursuant to Rule 10b5-1 trading plans adopted on April 23, 2026. Readnour has shared voting and dispositive power over these fund-held shares and disclaims beneficial ownership except to the extent of his pecuniary interest; a separate entry shows 9,077 shares of common stock held directly as of September 3, 2026.

Insider Trade Summary 10b5-1

Net Seller: 16,119 shares

Net Sell 5 txns

Insider Readnour Robin Shane

Role Director

Sold 16,119 shs ($97K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F3, F4, F5	4,725	$6.0183	$28K
Sale	Common Stock F2, F3, F4, F6	5,294	$6.0183	$32K
Sale	Common Stock F1, F3, F4, F5	2,877	$6.0698	$17K
Sale	Common Stock F2, F3, F4, F6	3,223	$6.0698	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 625,350 shares (Indirect, See footnotes); Common Stock — 9,077 shares (Direct)

Footnotes (6)

1. F1. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.
2. F2. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.
3. F3. Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
4. F4. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
5. F5. Shares held directly by MGC 2018 LP.
6. F6. Shares held directly by MGC 2018 QP.

Key Figures

Shares sold indirectly: 16,119 shares Weighted average sale price (September 8, 2026): $6.0183 per share Weighted average sale price (September 3, 2026): $6.0698 per share +2 more

5 metrics

Shares sold indirectly 16,119 shares Common Stock sold on September 3 and 8, 2026 by funds associated with the director

Weighted average sale price (September 8, 2026) $6.0183 per share Common Stock sales by related funds; prices within $6.000 to $6.085 range

Weighted average sale price (September 3, 2026) $6.0698 per share Common Stock sales by related funds; prices within $6.000 to $6.085 range

Direct holdings after transaction 9,077 shares Common Stock held directly by Robin Shane Readnour as of September 3, 2026

Rule 10b5-1 plan adoption date April 23, 2026 Trading plans for MGC Venture Partners 2018, LP and QP 2018, LP

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, shared dispositive power, pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"occurred automatically pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price for multiple transactions"

shared dispositive power financial

"has shared voting and shared dispositive power over the shares"

pecuniary interest financial

"disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest"

FAQ

What insider activity did AN2 Therapeutics (ANTX) report in this Form 4?

AN2 Therapeutics reported that director Robin Shane Readnour, through related investment funds, reported sales of 16,119 shares of ANTX common stock on September 3 and 8, 2026, executed automatically under Rule 10b5-1 trading plans adopted on April 23, 2026.

How many ANTX shares were sold and on which dates?

Related funds sold 16,119 ANTX shares in total: 6,100 shares on September 3, 2026 and 10,019 shares on September 8, 2026, according to the Form 4 transaction table.

At what prices were the ANTX shares sold in this Form 4?

The filing reports weighted average sale prices of $6.0698 per share on September 3, 2026 and $6.0183 per share on September 8, 2026, for transactions within a $6.000 to $6.085 price range.

Were the ANTX insider sales made under a Rule 10b5-1 trading plan?

Yes. Footnotes state the sales occurred automatically pursuant to Rule 10b5-1 trading plans adopted by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on April 23, 2026.

Does the ANTX director still hold shares directly after these transactions?

Yes. A holding entry shows Robin Shane Readnour with 9,077 ANTX common shares held directly as of September 3, 2026, separate from the shares held by the investment funds.

Who actually held the ANTX shares that were sold in this Form 4?

The sold shares were held by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP. Their general partner MGC 2018 GP shares voting and dispositive power; Readnour is associated with these entities and disclaims beneficial ownership beyond his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:43 PM Accepted by SEC EDGAR 09/08/2026 - 07:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Readnour Robin Shane

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		2,877	D	$6.0698(3)	562,715	I	See footnotes(4)(5)
Common Stock	09/03/2026		S(2)		3,223	D	$6.0698(3)	630,644	I	See footnotes(4)(6)
Common Stock	09/08/2026		S(1)		4,725	D	$6.0183(3)	557,990	I	See footnotes(4)(5)
Common Stock	09/08/2026		S(2)		5,294	D	$6.0183(3)	625,350	I	See footnotes(4)(6)
Common Stock								9,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

2. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

3. Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

4. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

5. Shares held directly by MGC 2018 LP.

6. Shares held directly by MGC 2018 QP.

	/s/ Eric Easom, Attorney-in-Fact for Robin Shane Readnour	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)